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1 |  BACKGROUND
The porphyrias are a group of genetic metabolic disorders 
caused by the partial deficiency of one of the enzymes in-
volved in the heme biosynthetic pathway. These disorders can 
be classified on the basis of their clinical manifestations into 
cutaneous, acute, and mixed porphyrias (Battle, 1997; Puy, 
Gouya, & Deybach, 2010).
Particularly, individuals with acute hepatic porphyrias 
(AHPs), where liver is the major site of expression of the 
enzymatic defect, suffer from neurovisceral attacks (Albers 
& Fink, 2004).
From the four AHPs, Acute Intermittent Porphyria (AIP) 
(OMIM: 176000) and Variegate Porphyria (VP) (OMIM: 
176200) are the most common type of acute porphyria in our 
country.
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Abstract
Background: Acute Hepatic Porphyrias (AHPs) are characterized by an acute neu-
roabdominal syndrome including both neuropsychiatric symptoms and neurodegen-
erative changes. Two main hypotheses explain the pathogenesis of nervous system 
dysfunction: (a) the ROS generation by autooxidation of 5-aminolevulinic acid ac-
cumulated in liver and brain; (b) liver heme deficiency and in neural tissues that 
generate an oxidative status, a component of the neurodegenerative process.
Methods: We review results obtained from Acute Intermittent Porphyria (AIP) and 
Variegate Porphyria (VP) families studied at clinical, biochemical, and molecular 
level at the CIPYP in Argentina. The relationship between the porphyric attack and 
oxidative stress was also evaluated in AHP patients and controls, to identify a marker 
of neurological dysfunction.
Results: We studied 116 AIP families and 30 VP families, 609 and 132 individuals, 
respectively. Genotype/phenotype relation was studied. Oxidative stress parameters 
and plasma homocysteine levels were measured in 20 healthy volunteers, 22 AIP and 
12 VP individuals.
Conclusion: No significant difference in oxidative stress parameters and homocyst-
eine levels between the analyzed groups were found.
K E Y W O R D S
acute hepatic porphyrias, acute intermittent porphyria, heme metabolism, oxidative stress, variegate 
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2 of 7 |   MARTINEZ ET Al.
AIP is an autosomal dominant disorder caused by a defi-
cient activity of hydroxymethylbilane synthase (HMBS) (EC 
4.3.1.8; OMIM: 609806), also referred to as porphobilinogen 
deaminase, producing a markedly increase in the urinary ex-
cretion of 5-aminolevulinic acid (ALA) and porphobilinogen 
(PBG). The symptoms may frequently generally appear at 
any time after puberty and are characterized by intermittent 
attacks of abdominal pain, constipation, vomiting, hyperten-
sion, tachycardia, fever, and various peripheral and central 
nervous system manifestations (Albers & Fink, 2004; Puy et 
al., 2010).
VP is an autosomal dominant disorder associated to a de-
ficiency of the penultimate enzyme of the heme biosynthetic 
pathway the Protoporphyrinogen oxidase (PPOX; EC 1.1.3.4; 
OMIM: 600923). Patients with VP may present a broad spec-
trum of clinical manifestations characterized by cutaneous 
photosensitivity and neurological symptoms which can occur 
separately or together in affected individuals. Cutaneous 
photosensitivity is characterized by skin fragility, erosions, 
blisters, millia, and pigmentary changes in sun exposed areas. 
Neurological symptoms are similar to those of AIP.
Acute attacks in latent individuals can be induced by a 
variety of environmental factors including many common 
medications, nutritional factors, restricted carbohydrate, and 
calories intake, hormones (Albers & Fink, 2004). A com-
mon mechanism of these triggering agents is to increase the 
hepatic heme demand as a consequence of the induction of 
their metabolizing enzymes, CYP450, which have heme as 
a prosthetic group. The hepatic heme pool is reduced and 
consequently the first and limiting enzyme of the pathway, 
5-aminolevulinic synthase (ALAS1; OMIM: 125290), is in-
duced, so the synthesis of its product ALA is increased. In 
individuals with a partial deficiency in one of the enzymes 
of heme biosynthesis, the deficient enzyme becomes limiting 
and precursors (ALA and PBG) accumulate.
The biochemical events in AHPs are characterized by a 
massive accumulation and excretion of ALA and PBG during 
the neurovisceral attack. Even though ALA is neurotoxic, the 
exact mechanism by which this precursor carries out their ac-
tion is not yet known and the pathogenesis of nervous system 
dysfunction remains unclear (Dwyer, Stone, Zhu, Perry, & 
Smith, 2006). There is a hypothesis which states that ALA 
can oxidase itself generating Reactive Oxygen Species (ROS) 
which increase the oxidative stress in the cell, thus explaining 
the porphyric attack (Onuki et al., 2004).
Another hypothesis is based on heme deficiency in liver 
and neural tissues impairing critical processes depending on 
hemoproteins (Dwyer et al., 2006). The heme deficiency can 
be a crucial component of the neurodegenerative process 
(Atamna, Killilea, Killilea, & Ames, 2001). Furthermore, 
there are alterations of heme biosynthetic pathway associ-
ated with Alzheimer's disease, where the oxidative damage 
is present since early stages with neurological dysfunction 
(Atamna & Frey, 2004). This is due to an oxidative stress 
as a consequence of an elevation of homocysteine levels in 
plasma which mobilizes iron storage from ferritin (Dwyer, 
Raina, Perry, & Smith, 2004).
In this paper, we review same results obtained from the 
AIP and VP families studied at biochemical and molecu-
lar level at the CIPYP in Argentina (Cerbino et al., 2015; 
Rossetti, Granata, Giudice, Parera, & Batlle, 2008). Taking 
into account the relationship between the porphyric attack 
and oxidative stress, we also decided to study oxidative stress 
parameters and homocysteine levels in AHP patients and 
controls, to identify a marker of neurological dysfunction.
2 |  MATERIALS AND METHODS
Informed consent was obtained from all patients following 
the standards of UNESCO Declarations-DDHH Genome 
and Genetic Data (http://www.unesco.org/shs/ethics). 
Declaration of Helsinki was taken into consideration, and 
the study was approved by the Institutional Research Ethics 
Committee (CIPYP, CONICET – UBA).
From March 1994 to December 2016, 153 unrelated fami-
lies, mostly from Argentina, were studied at biochemical and 
molecular level. All patients had current symptoms of AIP 
or VP and the diagnosis was made on the basis of their clin-
ical history of at least one acute attack or, in VP patients, 
typical cutaneous lesions, associated with increased excretion 
of ALA, PBG, and total porphyrins in urine and plasma in 
AIP and also in feces for VP (Méndez et al., 2012). The final 
diagnosis of the patients was established by genetic studies. 
Unrelatedness was determined by family inquiries.
Genetic studies were done according to the methodologies 
described in Cerbino et al., 2015 and Rossetti et al., 2008.
The Human Gene Mutation Database (http://www.hgmd.
cf.ac.uk/) was used for information about reported mutations 
in the HMBS and PPOX gen.
2.1 | Oxidative stress and neurological 
damage parameters
Plasma was obtained from anticoagulated blood samples by 
centrifugation at 1500 g for 10 min. There were three groups 
included in the study: AIP individuals (N = 22), VP (N = 12), 
and healthy volunteers (N = 20).
The determination of oxidative state and antioxidant de-
fenses where performed according to the following methods: 
the total oxidant state, Erel (2005); malondialdehyde levels 
(MDA), Grotto et al. (2007); oxidative damage to proteins, 
Reznick and Packer (1993); reduced glutathione (GSH) lev-
els, Rossi, Cardaioli, Scaloni, Amiconi, and Simplicio (1995); 
the total antioxidant capacity, Erel (2004); Catalase activity, 
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Chance and Maehly (1965). The determination of plasma ho-
mocysteine levels was performed according to the method of 
Krijt, Vackova, and Kožich (2001). Protein content was mea-
sured by Lowry, Rosebrough, Farr, and Randall (1951).
The experiments were performed in duplicate and results 
were expressed as the mean ± standard deviation. Statistical 
analysis was performed using one-way ANOVA to determine 
the differences between groups. It was considered that the 
difference between the patient and the control groups was 
significant at p < .05.
3 |  RESULTS
3.1 | Study of AIP families
During the last 30 years, 116 families were biochemically 
and genetically diagnosed as AIP at the CIPYP. We analyzed 
609 individuals (417 women and 192 men).The results from 
this analysis were shown in Figure 1a,b.
Of the total missense mutations, p.G111R (NM_000190.4 
(HMBS): c.331G>A (p.Gly111Arg)) corresponds to 72.3%, 
the most prevalent in Argentina (56.3%), for which we had 
described a founder effect (Cerbino et al., 2015) (Figure 1b). 
No genotype/phenotype relationship was found in our AIP 
patients (Figure 1c).
3.2 | Study of VP families
We studied at molecular level, 36 families as VP, including 
a total of 132 individuals, of which, 68.94% carried the cor-
responding VP mutation. The results were shown in Figure 
2. The insertion, c.1042_1043insT, (34.6%) was a prevalent 
mutation only reported in Argentina (Rossetti et al., 2008), 
is due to a founder effect among our population (Granata, 
Parera, Batlle, & Rossetti, 2015).
We did not find a genotype/phenotype correlation in VP 
patients (Figure 2b,c).
3.3 | Acute porphyrias and oxidative stress
In AIP and VP patients, total oxidant capacity and oxidative 
damage markers as lipid peroxidation (MDA levels) and 
oxidative damage to proteins were assessed. We observed 
that there were no significant differences between patients 
and controls (Table 1). Regarding the antioxidant defense, 
F I G U R E  1  (a) Percentage distribution of AIP-mutated individuals by sex and according to clinical and biochemical manifestation. (b) 
Percentage distribution of the four types of AIP mutations found in Argentina. The subgraph shows the distribution of p.G111R (NM_000190.4 
(HMBS): c.331G>A (p.Gly111Arg)) mutation among the total missense mutations. (c) Distribution of individuals carrying an AIP mutation 
according to symptomatology, sex, and the type of genetic variant
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levels of GSH, catalase activity and total antioxidant capac-
ity were assessed, finding similar values between patients 
and controls. We determined plasma levels of total homo-
cysteine, a marker of neurologic damage, finding no sig-
nificant differences between the analyzed groups (Table 1).
4 |  DISCUSSION
From the families diagnosed at the molecular level, in studied 
period, the percentage of latent individuals was significant 
and similar in both porphyrias (about 44%).
F I G U R E  2  (a) Percentage distribution of the four types of VP mutations found in Argentina. The subgraph shows the distribution 
of c.1.042_1.043insT mutation among the total insertion mutations. (b) Percentage distribution of VP mutated individuals according to 
symptomatology. (c) Percentage distribution of Genotype/Phenotype correlation according to symptomatology and genetic variant. (d) Distribution 
of Individuals carrying VP mutation according to symptomatology and the type of genetic variant
T A B L E  1  Oxidative status, antioxidant defense, and neurological damage parameters assayed
Parameter Controls VP AIP
Oxidative status
Total oxidant capacity (μmol/L) 15.19 ± 3.16 17.63 ± 4.05 19.22 ± 4.96
MDA (nmol/ml) 0.68 ± 0.05 0.75 ± 0.06 0.82 ± 0.06
Protein damage (nmol/mg) 1.81 ± 0.42 2.12 ± 0.44 2.33 ± 0.52
Antioxidant defense
GSH (μmol/ml) 0.39 ± 0.03 0.52 ± 0.04 0.48 ± 0.04
Total antioxidant capacity (μmol/L) 939 ± 103 752 ± 124 735 ± 143
Catalase (nmol min−1 ml−1) 16.7 ± 4.7 20.5 ± 7.0 20.3 ± 7.2
Neurological damage
Homocysteine (mmol/L) 10.7 ± 3.2 14.6 ± 4.3 15.2 ± 3.9
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The relationship between women and men who had a clin-
ical episode during their lifetime was 10:1, regardless of the 
type of AIP mutation they have. This is because women are 
more exposed to the factors that can trigger the typical acute 
attacks of AIP.
Of the amount of healthy carriers detected from the anal-
ysis of genetic studies arises the importance of doing these 
studies in asymptomatic individuals in diagnosed families. 
Thus, it is possible to advice these people about porphyrino-
genic drugs or behaviors (fasting, diet, hormonal treatments, 
alcohol, etc.) that can lead to porphyria triggering.
In this study, it was not possible to extract data for a pos-
sible correlation between symptomatology and a type of 
mutation, although genotype–phenotype correlation could 
be established in the Finnish population (von und, 2002; zu 
Fraunberg, Timonen, Mustajoki, & Kauppinen,). This lack of 
genotype–phenotype relationship was previously reported in 
Argentina (Rossetti et al., 2008), as well as in other popula-
tions (Schneider-Yin & Minder, 2006; Whatley et al., 1999). 
In general, we can say that apparently a given genotype is not 
the only determinant of the clinical presentation of porphyria 
(Monteiro, Abdalla, Faljoni-Alàrio, & Bechara, 1985), in ac-
cordance with the multifactorial nature of this disease.
ALA accumulation in these porphyrias is an endogenous 
ROS source that can produce irreversible damage to cellular 
components (Monteiro et al., 1985). Furthermore, increased 
ROS relates to the pathogenesis of neurological dysfunction 
in diseases such as Alzheimer disease (AD) (Atamna & Frey, 
2004). There is evidence of alterations of heme synthesis in 
cortical tissues from clinically and pathologically confirmed 
cases of AD (Dwyer, Smith, Richardson, Perry, & Zhu, 2009).
In previous reports, no alterations were detected in the 
antioxidant defense system in the plasma of VP patients, 
only a slight increase in MDA was found (Ferrer, Tauler, 
Sureda, Romaguera, et al., 2009). However, some alterations 
of oxidative stress and inflammation markers were found in 
erythrocytes, neutrophils, and lymphocytes of VP patients, 
a decrease of antioxidant capacity and increase of ROS pro-
duction in neutrophils and stimulated lymphocytes (Ferrer et 
al., 2010; Ferrer, Tauler, Sureda, Palacín, et al., 2009; Ferrer, 
Tauler, Sureda, Romaguera, et al., 2009). Also, in AIP pa-
tients there are reports of high levels of plasma homocyste-
ine, finding no relationship at all between them and the levels 
of heme precursors excreted in urine or clinical presentation 
of the disease (To-Figueras, Lopez, Deulofeu, & Herrero, 
2010).
In this work we could not find significant differences in 
plasma of porphyric individuals and controls in any of the pa-
rameters studied. It is likely that early diagnosis of porphyria 
in these patients and their constant follow-up leads to a situa-
tion where ROS levels and the state of the antioxidant defense 
system are balanced. Moreover it is of note to mention that 
our patients, most of them without repetitive acute attacks, 
are successfully treated daily with a glucose infusion, vitamin 
B12 complex and folic acid (Wider de Xifra, Batlle, Stella, 
& Malamud, 1980) since we have already demonstrated that 
it enhanced HMBS activity, the deficient enzyme in AIP 
and also a second point of regulation in VP (De Geralnik, 
Rossetti, & Batlle, 1981; Ferrer, Tauler, Sureda, Palacín, et 
al., 2009). Although it is not known if neuronal homocysteine 
would be responsive to dietary measures, it was observed that 
an increase in dietary folate reduces plasma homocysteine. 
This could be explained because in brain the homocysteine 
could be remethylated to methionine by a 5-methyltetrahy-
drofolate and vitamin B12-dependent pathway. Moreover, by 
the transsulfuration pathway homocysteine is converted in 
cysteine for the synthesis of glutathione, involving cystathi-
onine β-synthase (CβS) and cystathionine γ-lyase. Although 
this pathway is negligible in neural tissue because brain lacks 
the last enzyme, CβS is present and explains the high levels 
of cystathionine found in brain tissue. CβS is also a folate-de-
pendent enzyme and although it is activated in oxidative con-
ditions, its redox regulation is lost in the absence of heme. 
The reduced CβS activity produced elevated neuronal homo-
cysteine levels which mobilizes iron storage from ferritin, 
leading to a vicious circle involving disrupted iron homeosta-
sis. This oxidative stress status is responsible for degenerative 
neuronal disease (Dwyer et al., 2004, 2006).
On the basis of these findings, it could be hypothesized 
that daily folate and vitamin B12 supplements in our patients 
would also decrease brain homocysteine to levels which 
could prevent or alleviate the oxidative damage. Furthermore, 
in the case of patients it is impossible to evaluate the redox 
status and antioxidant defenses directly into the affected or-
gans. Assessing these parameters in biological samples such 
as plasma or urine, may not reflect irrefutably what happens 
in the organs until their deterioration being severe.
In conclusion, although we were not able to find any signif-
icant difference in the parameters measured between control 
group and porphyric patients, we consider that it would be rel-
evant to carry out an extensive study to demonstrate that a pro-
found heme deficiency in acute porphyrias could be, at least, 
one of the reasons accounting for the neurodegenerative dam-
age observed in characteristic acute attacks in AHPs patients.
ACKNOWLEDGMENTS
The authors thank to H Muramatsu MD, Dr. MN Guolo, Lic. LS 
Varela, Dr. G. Noriega, Lic. PLR Winitzky, Dra. LM Oliveri, 
Mrs VI Castillo and FA Caballero for their technical assistance.
CONFLICT OF INTEREST
The authors report no conflict of interest.
AUTHOR CONTRIBUTION
Martinez M del C, Cerbino GN and Granata BX: carried out 
the experimental studies and analysis of data and draft the 
6 of 7 |   MARTINEZ ET Al.
manuscript. Batlle Alcira: contributed to writing the manu-
script. Parera VE: supervised biochemical studies in Argentine 
patients. Rossetti MV: guarantor; conception, design, and su-
pervision of the whole work; and revising the manuscript. All 
authors read and approved the final manuscript.
ETHICAL APPROVAL
Written informed consent was obtained from all patients 
prior to their inclusion in the study. The study protocol 
was approved by the Ethical Committee of the Centro de 
Investigaciones sobre Porfirinas y Porfirias (CIPYP—
Hospital de Clínicas, CONICET- UBA) and was performed 
in accordance with the Helsinki Declaration of 1964 and 
its modifications (Tokyo, Japon 1975; Venece, Italy, 1983; 
Hong Kong, 1989; South Africa, 1996; Edimburg, Scotland, 
2000; Washington, USA, 2002; Tokyo, 2004; Seul, Korea, 
2008; Fortaleza, Brazil, 2013).
ORCID
María del Carmen Martinez   https://orcid.
org/0000-0002-5538-6620 
Gabriela Nora Cerbino   https://orcid.org/0000-0002-2906-5153 
María Victoria Rossetti   https://orcid.org/0000-0002-4380-6253 
REFERENCES
Albers, J. W., & Fink, J. K. (2004). Porphyric neuropathy. Muscle and 
Nerve, 30, 410–422. https ://doi.org/10.1002/mus.20137 
Atamna, H., & Frey, W. H. II (2004). A role for heme in Alzheimer's 
disease: Heme binds amyloid beta and has altered metabolism. 
Proceedings of the National Academy of Sciences of the United 
States of America, 101, 11153–11158. https ://doi.org/10.1073/
pnas.04043 49101 
Atamna, H., Killilea, D. W., Killilea, A. N., & Ames, M. (2001). Heme 
deficiency may be a factor in the mitocondrial and neuronal decay 
of aging. Proceedings of the National Academy of Sciences of the 
United States of America, 99, 14807–14812. https ://doi.org/10.1073/
pnas.19258 5799
Batlle, A. M. (1997). Porfirias Humanas. Signos y Tratamientos. 
Porfirias y porfirinas. Aspectos clínicos, bioquímicos y biología 
molecular. Actualizaciones Médicas Bioquímicas. Ed. Federación 
Bioquímica De La Provincia De Buenos Aires. Acta Bioquím 
Latinoamer. Buenos Aires-Argentina.
Cerbino, G. N., Gerez, E. N., Varela, L. S., Melito, V. A., Parera, V. E., 
Batlle, A., & Rossetti, M. V. (2015). Acute Intermittent porphyria 
in Argentina: An update. BioMed Research International, 2015, 
1–8.https ://doi.org/10.1155/2015/946387
Chance, B., & Moehly, A. (1965). Assay of catalases and peroxidases. 
In S. P. Colowick, & N. O. Kaplan (Eds.), Methods in enzymology 
(Vol. II, pp. 764–768). New York: Academic Press.
De Geralnik, A. A., Rossetti, M. V., & Batlle, A. M. C. (1981). Porphyrin 
biosynthesis in Euglena gracilis-IV. An endogenous factor controlling 
the enzymic synthesis of porphyrinogens and its possible role in the 
treatment of some porphyrias. International Journal of Biochemistry, 
13, 343–353. https ://doi.org/10.1016/0020-711x(81)90088-4
Dwyer, B. E., Raina, A. K., Perry, G., & Smith, M. A. (2004). 
Homocysteine and Alzheimer's disease: A modifiable risk? 
Free Radical Biology and Medicine, 36, 1471–1475. https ://doi.
org/10.1016/j.freer adbio med.2004.03.009
Dwyer, B. E., Smith, M. A., Richardson, S. L., Perry, G., & Zhu, X. 
(2009). Down-regulation of aminolevulinate synthase, the rate-lim-
iting enzyme for heme biosynthesis in Alzheimer's disease. 
Neuroscience Letters, 460, 180–184. https ://doi.org/10.1016/j.
neulet.2009.05.058
Dwyer, B. E., Stone, M. L., Zhu, X., Perry, G., & Smith, M. A. (2006). 
Heme deficiency in Alzheimer's disease: A possible connection to 
porphyria. Journal of Biomedicine & Biotechnology, 2006, 24038. 
https ://doi.org/10.1155/JBB/2006/24038 
Erel, O. (2004). A novel automated direct measurement method for total 
antioxidant capacity using a new generation, more stable ABTS 
radical cation. Clinical Biochemistry, 37, 277–285. https ://doi.
org/10.1016/j.clinb iochem.2003.11.015
Erel, O. (2005). A new automated colorimetric method for measuring 
total oxidant status. Clinical Biochemistry, 38, 1103–1111. https ://
doi.org/10.1016/j.clinb iochem.2005.08.008
Ferrer, M. D., Sureda, A., Tauler, P., Palacín, C., Tur, J. A., & Pons, 
A. (2010). Impaired lymphocyte mitochondrial antioxidant de-
fences in variegate porphyria are accompanied by more in-
ducible reactive oxygen species production and DNA damage. 
British Journal of Haematology, 149, 759–767. https ://doi.
org/10.1111/j.1365-2141.2010.08149.x
Ferrer, M. D., Tauler, P., Sureda, A., Palacín, C., Tur, J. A., & Pons, A. 
(2009). Variegate porphyria induces plasma and neutrophil oxida-
tive stress: Effects of dietary supplementation with vitamins E and 
C. British Journal of Nutrition, 103, 69–76. https ://doi.org/10.1017/
S0007 11450 9991413
Ferrer, M. D., Tauler, P., Sureda, A., Romaguera, D., Llompart, I., 
Palacin, C., … Pons, A. (2009). Enzyme antioxidant defences and 
oxidative damage in red blood cells of variegate porphyria patients. 
Redox Report, 14, 69–74. https ://doi.org/10.1179/13510 0009X 
392502
Granata, B. X., Parera, V. E., Batlle, A., & Rossetti, M. V. (2015). 
Haplotype study in Argentinean variegate porphyria patients. 
Human Heredity, 80, 139–143. https ://doi.org/10.1159/00044 
5749
Grotto, D., Santa Maria, L. D., Boeira, S., Valentini, J., Charão, M. 
F., Moro, A. M., … Garcia, S. C. (2007). Rapid quantification 
of malondialdehyde in plasma by high performance liquid chro-
matography–visible detection. Journal of Pharmaceutical and 
Biomedical Analysis, 44, 619–624. https ://doi.org/10.1016/j.
jpba.2006.07.030
Krijt, J., Vackova, M., & Kožich, V. (2001). Measurement of homo-
cysteine and other aminothiols in plasma: Advantages of using tris 
(2-carboxyethyl) phosphine as reductant compared with tri-n-butyl-
phosphine. Clinical Chemistry, 47, 1821–1828.
Lowry, O., Rosebrough, N., Farr, A., & Randall, R. (1951). Protein 
measurement with the Folin-phenol reagent. Journal of Biological 
Chemistry, 193, 265–275.
Méndez, M., Granata, B. X., Moran Jiménez, M. J., Parera, V. E., Batlle, 
A., Enriquez de Salamanca, R., & Rossetti, M. V. (2012). Fuctional 
chractererization of five protoporphyrinogen oxidase missense mu-
tations found in Argentinean variegate patients. JIMD Reports, 4, 
91–97. https ://doi.org/10.1007/8904_2011_77
Monteiro, H. P., Abdalla, D. S., Faljoni-Alàrio, A., & Bechara, E. J. (1985). 
Generation of active oxygen species during coupled autoxidation of oxy-
hemoglobin and delta-aminolevulinic acid. Biochimica et Biophysica 
Acta, 881, 100–106. https ://doi.org/10.1016/0304-4165(86)90102-9
   | 7 of 7MARTINEZ ET Al.
Onuki, J., Chen, Y., Teixeira, P. C., Schumacher, R. I., Medeiros, M. 
H., Van Houten, B., & Di Mascio, P. (2004). Mitochondrial and 
nuclear DNA damage induced by 5-aminolevulinic acid. Archives 
of Biochemistry and Biophysics, 432, 178–187. https ://doi.
org/10.1016/j.abb.2004.09.030
Puy, H., Gouya, L., & Deybach, J. C. (2010). Porphyrias. The Lancet, 
375, 924–937. https ://doi.org/10.1016/S0140-6736(09)61925-5
Reznick, A. Z., & Packer, L. (1993). Oxidative damage to proteins: 
Spectrophotometric method for carbonyl assay. Methods in enzymol-
ogy (Vol. 233, pp. 357–363). New York: Academic Press.
Rossetti, M. V., Granata, B. X., Giudice, J., Parera, V. E., & Batlle, A. 
(2008). Genetic and biochemical studies in Argentinean patients 
with variegate porphyria. BMC Medical Genetics, 9, 54. https ://doi.
org/10.1186/1471-2350-9-54
Rossi, R., Cardaioli, E., Scaloni, A., Amiconi, G., & Di Simplicio, P. 
(1995). Thiol groups in protein as endogenous reductants to de-
termine glutathione protein mixed disulphides in biological sys-
tems. Biochimica et Biophysica Acta, 1243, 230–238. https ://doi.
org/10.1016/0304-4165(94)00133-i
Schneider-Yin, X., & Minder, E. I. (2006). Swiss patients with varie-
gate porphyria have unique mutations. Swiss Medical Weekly, 136, 
515–519. 2006/31/smw-11472 
To-Figueras, J., Lopez, R. M., Deulofeu, R., & Herrero, C. (2010). 
Preliminary report: Hyperhomocysteinemia in patients with acute 
intermittent porphyria. Metabolism, 59, 1809–1810. https ://doi.
org/10.1016/j.metab ol.2010.05.016
von und zu Fraunberg, M., Timonen, K., Mustajoki, P., & Kauppinen, 
R. (2002). Clinical and biochemical characteristics and geno-
type-phenotype correlation in Finnish Variegate Porphyria patients. 
European Journal of Human Genetics, 10, 649–657. https ://doi.
org/10.1038/sj.ejhg.5200860
Whatley, S. D., Puy, H., Morgan, R. R., Robreau, A. M., Roberts, A. 
G., Nordmann, Y., … Deybach, J. C. (1999). Variegate porphyria in 
Western Europe: Identification of PPOX gene mutations in 104 fam-
ilies, extent of allelic heterogeneity, and absence of correlation be-
tween phenotype and type of mutation. American Journal of Human 
Genetics, 65, 984–994. https ://doi.org/10.1086/302586
Wider de Xifra, E. A., Batlle, A. M., Stella, A. M., & Malamud, S. 
(1980). Acute intermittent porphyria. Another approach to therapy. 
International Journal of Biochemistry, 12, 812–822. https ://doi.
org/10.1016/0020-711x(80)90169-x
How to cite this article: Martinez MDC, Cerbino 
GN, Granata BX, Batlle A, Parera VE, Rossetti MV. 
Clinical, biochemical, and genetic characterization of 
acute hepatic porphyrias in a cohort of Argentine 
patients. Mol Genet Genomic Med. 2019;00:e1059. 
https ://doi.org/10.1002/mgg3.1059
